All In MedTech

Device Trial Radar · NCT06970899

Initial Feasibility Study of the CycloPE® Device

Evaluation of the CycloPE® Device Used in Patients With a Suspected Bloodstream Infection

Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Actual

Start

Jun 11, 2024

Primary completion

Apr 26, 2025

Study completion May 15, 2025

Sponsor

Lead sponsor
PATH EX, Inc.Not on our public-company list
Sponsor type
Industry
First posted
May 14, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center, prospective, single-arm clinical study to evaluate the feasibility, safety, and performance of the PATH EX CycloPE® device on suspected bacteremia-associated sepsis. All participants are adults diagnosed with suspected bacteremia-associated sepsis, admitted to the intensive care unit (ICU), and meet the inclusion criteria.

Conditions

  • Sepsis
  • Infection
  • Bacteremia Sepsis
  • Systemic Inflammatory Response Syndrome (SIRS)

Interventions

  • PATH EX CycloPE® DeviceDevice

    Participants in this arm will receive two extracorporeal blood filtration treatments using the PATH EX CycloPE® device. The first treatment will be initiated following baseline assessments, and the second treatment will occur 24-36 hours after the start of the first treatment. Each treatment will last up to 4 hours. The device is designed to target and remove bacteria from the bloodstream. All participants will also receive standard-of-care treatment for sepsis, including IV antibiotics, as determined by the treating physician.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serious Adverse Events (SAEs) related to the investigational deviceTime frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Erebuni Medical Cener

    Yerevan, Armenia, Armenia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.